Evidence map›Paper›PMID 27568860›Full record

ArticleAllergy2017

Heat-labile Escherichia coli toxin enhances the induction of allergen-specific IgG antibodies in epicutaneous patch vaccination.

C R Cabauatan, R Campana, K Niespodziana, C Reinisch, U Lundberg, A Meinke, R Henning, A Neubauer, R Valenta

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Next generation immunotherapy for tree pollen allergies.Human vaccines & immunotherapeutics · 2017
    Review
  4. Article
  5. Molecular aspects of allergens in atopic dermatitis.Current opinion in allergy and clinical immunology · 2017
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

C R CabauatanDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
R CampanaDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
K NiespodzianaDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
C ReinischValneva Austria GmbH, Campus Vienna Biocenter, Vienna, Austria.
U LundbergValneva Austria GmbH, Campus Vienna Biocenter, Vienna, Austria.
A MeinkeValneva Austria GmbH, Campus Vienna Biocenter, Vienna, Austria.
R HenningBiomay AG, Vienna, Austria.
A NeubauerBiomay AG, Vienna, Austria.
R ValentaDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Medical University of Vienna · ATBiomay (Austria) · ATVienna Biocenter · ATValneva (Austria) · AT

Funding

Austrian Science Fund FWF F 4605
6 · The paper itself

Abstract

Epicutaneous allergen-specific immunotherapy (EPIT) is proposed as an alternative route for allergen-specific immunotherapy (AIT). The induction of allergen-specific blocking IgG antibodies represents an important mechanism underlying AIT, but has not been investigated for EPIT. Here, we compared the induction of allergen-specific blocking IgG in outbred guinea pigs which had been immunized with recombinant birch pollen allergen Bet v 1 using patch delivery system (PDS) with or without heat-labile toxin (LT) from Escherichia coli or subcutaneously with aluminum hydroxide (Alum)-adsorbed rBet v 1. Only subcutaneous immunization with Alum-adsorbed rBet v 1 and epicutaneous administration of rBet v 1 with PDS in combination with LT from E. coli induced allergen-specific IgG antibodies blocking allergic patients' IgE, but not immunization with rBet v 1 via PDS alone. Our results suggest that patch vaccination with rBet v 1 in combination with LT may be a promising strategy for allergen-specific immunotherapy against birch pollen allergy.

Indexed as

Desensitization, ImmunologicTransdermal PatchVaccinationAllergensAnimalsAntibody SpecificityAntigens, PlantBacterial ToxinsEnterotoxinsEscherichia coli ProteinsFemaleGuinea PigsImmunizationImmunoglobulin EImmunoglobulin GRecombinant ProteinsAllergensAntigens, PlantBacterial ToxinsEnterotoxinsEscherichia coli Proteinsheat-labile enterotoxin, E coliImmunoglobulin EImmunoglobulin GRecombinant Proteinsallergen-specific immunotherapyepicutaneous allergen-specific immunotherapyheat-labile Escherichia coli toxinpatch delivery systemrBet v 1

Identifiers

PMID27568860
PMCPMC5215485
OpenAlexW2507778068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.